Literature DB >> 26552818

Next-Generation Analysis of Deep Sequencing Data: Bringing Light into the Black Box of SELEX Experiments.

Michael Blank1.   

Abstract

In silico analysis of next-generation sequencing data (NGS; also termed deep sequencing) derived from in vitro selection experiments enables the analysis of the SELEX procedure (Systematic Evolution of Ligands by EXponential enrichment) in an unprecedented depth and improves the identification of aptamers. Besides quality control and optimization of starting libraries, advanced screening strategies for difficult targets or early identification of rare but high quality aptamers which are otherwise lost in the in vitro selection experiments become possible. The high information content of sequence data obtained from selection experiments is furthermore useful for subsequent lead optimization.

Keywords:  Bioinformatics; In silico analysis; NGS; Next generation sequencing; SELEX

Mesh:

Substances:

Year:  2016        PMID: 26552818     DOI: 10.1007/978-1-4939-3197-2_7

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  10 in total

1.  Identification and characterization of nucleobase-modified aptamers by click-SELEX.

Authors:  Franziska Pfeiffer; Fabian Tolle; Malte Rosenthal; Gerhard Markus Brändle; Jörg Ewers; Günter Mayer
Journal:  Nat Protoc       Date:  2018-04-26       Impact factor: 13.491

Review 2.  Applications of High-Throughput Sequencing for In Vitro Selection and Characterization of Aptamers.

Authors:  Nam Nguyen Quang; Gérald Perret; Frédéric Ducongé
Journal:  Pharmaceuticals (Basel)       Date:  2016-12-10

Review 3.  Key Aspects of Nucleic Acid Library Design for in Vitro Selection.

Authors:  Maria A Vorobyeva; Anna S Davydova; Pavel E Vorobjev; Alya G Venyaminova
Journal:  Int J Mol Sci       Date:  2018-02-05       Impact factor: 5.923

4.  Systematic evaluation of error rates and causes in short samples in next-generation sequencing.

Authors:  Franziska Pfeiffer; Carsten Gröber; Michael Blank; Kristian Händler; Marc Beyer; Joachim L Schultze; Günter Mayer
Journal:  Sci Rep       Date:  2018-07-19       Impact factor: 4.379

5.  Targeting hormone refractory prostate cancer by in vivo selected DNA libraries in an orthotopic xenograft mouse model.

Authors:  Laia Civit; Ioanna Theodorou; Franziska Frey; Holger Weber; Andreas Lingnau; Carsten Gröber; Michael Blank; Chloé Dambrune; James Stunden; Marc Beyer; Joachim Schultze; Eicke Latz; Frédéric Ducongé; Michael H G Kubbutat; Günter Mayer
Journal:  Sci Rep       Date:  2019-03-21       Impact factor: 4.379

Review 6.  Inside the Black Box: What Makes SELEX Better?

Authors:  Natalia Komarova; Alexander Kuznetsov
Journal:  Molecules       Date:  2019-10-07       Impact factor: 4.411

Review 7.  Implementation of High-Throughput Sequencing (HTS) in Aptamer Selection Technology.

Authors:  Natalia Komarova; Daria Barkova; Alexander Kuznetsov
Journal:  Int J Mol Sci       Date:  2020-11-20       Impact factor: 5.923

8.  Aptamer loaded superparamagnetic beads for selective capturing and gentle release of activated protein C.

Authors:  Nasim Shahidi Hamedani; Felix Lucian Happich; Eva-Maria Klein; Heiko Rühl; Günter Mayer; Johannes Oldenburg; Jens Müller; Bernd Pötzsch
Journal:  Sci Rep       Date:  2022-04-30       Impact factor: 4.996

9.  RNA Aptamers Recognizing Murine CCL17 Inhibit T Cell Chemotaxis and Reduce Contact Hypersensitivity In Vivo.

Authors:  Lorenz Fülle; Nancy Steiner; Markus Funke; Fabian Gondorf; Franziska Pfeiffer; Julia Siegl; Friederike V Opitz; Silvana K Haßel; Anna Belen Erazo; Oliver Schanz; H James Stunden; Michael Blank; Carsten Gröber; Kristian Händler; Marc Beyer; Heike Weighardt; Eicke Latz; Joachim L Schultze; Günter Mayer; Irmgard Förster
Journal:  Mol Ther       Date:  2017-10-13       Impact factor: 11.454

Review 10.  Therapeutic applications of nucleic acid aptamers in microbial infections.

Authors:  Shima Afrasiabi; Maryam Pourhajibagher; Reza Raoofian; Maryam Tabarzad; Abbas Bahador
Journal:  J Biomed Sci       Date:  2020-01-03       Impact factor: 8.410

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.